Literature DB >> 30033370

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

David A Quigley1, Ha X Dang2, Shuang G Zhao3, Paul Lloyd4, Rahul Aggarwal4, Joshi J Alumkal5, Adam Foye4, Vishal Kothari6, Marc D Perry6, Adina M Bailey4, Denise Playdle4, Travis J Barnard6, Li Zhang4, Jin Zhang7, Jack F Youngren4, Marcin P Cieslik8, Abhijit Parolia8, Tomasz M Beer9, George Thomas10, Kim N Chi11, Martin Gleave12, Nathan A Lack12, Amina Zoubeidi12, Robert E Reiter13, Matthew B Rettig14, Owen Witte15, Charles J Ryan16, Lawrence Fong4, Won Kim4, Terence Friedlander4, Jonathan Chou4, Haolong Li6, Rajdeep Das6, Hui Li6, Ruhollah Moussavi-Baygi6, Hani Goodarzi17, Luke A Gilbert18, Primo N Lara19, Christopher P Evans20, Theodore C Goldstein21, Joshua M Stuart22, Scott A Tomlins23, Daniel E Spratt3, R Keira Cheetham24, Donavan T Cheng24, Kyle Farh24, Julian S Gehring24, Jörg Hakenberg24, Arnold Liao24, Philip G Febbo24, John Shon24, Brad Sickler24, Serafim Batzoglou24, Karen E Knudsen25, Housheng H He26, Jiaoti Huang27, Alexander W Wyatt12, Scott M Dehm28, Alan Ashworth29, Arul M Chinnaiyan30, Christopher A Maher31, Eric J Small32, Felix Y Feng33.   

Abstract

While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor/38X normal coverage), we identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches. Notably, we observed amplification of an intergenic enhancer region 624 kb upstream of the androgen receptor (AR) in 81% of patients, correlating with increased AR expression. Tandem duplication hotspots also occur near MYC, in lncRNAs associated with post-translational MYC regulation. Classes of structural variations were linked to distinct DNA repair deficiencies, suggesting their etiology, including associations of CDK12 mutation with tandem duplications, TP53 inactivation with inverted rearrangements and chromothripsis, and BRCA2 inactivation with deletions. Together, these observations provide a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRCA2; androgen receptor; castration resistant prostate cancer; chromothripsis; gene fusion; genomics; metastases; structural variation; tandem duplication; whole-genome sequencing

Mesh:

Substances:

Year:  2018        PMID: 30033370      PMCID: PMC6425931          DOI: 10.1016/j.cell.2018.06.039

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  69 in total

1.  A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3.

Authors:  Pablo Cingolani; Adrian Platts; Le Lily Wang; Melissa Coon; Tung Nguyen; Luan Wang; Susan J Land; Xiangyi Lu; Douglas M Ruden
Journal:  Fly (Austin)       Date:  2012 Apr-Jun       Impact factor: 2.160

2.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.

Authors:  Scott A Tomlins; Bharathi Laxman; Saravana M Dhanasekaran; Beth E Helgeson; Xuhong Cao; David S Morris; Anjana Menon; Xiaojun Jing; Qi Cao; Bo Han; Jindan Yu; Lei Wang; James E Montie; Mark A Rubin; Kenneth J Pienta; Diane Roulston; Rajal B Shah; Sooryanarayana Varambally; Rohit Mehra; Arul M Chinnaiyan
Journal:  Nature       Date:  2007-08-02       Impact factor: 49.962

Review 3.  Chromothripsis and human disease: piecing together the shattering process.

Authors:  Christopher A Maher; Richard K Wilson
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

4.  CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield.

Authors:  Michael G Holmes; Erik Foss; Gabby Joseph; Adam Foye; Brooke Beckett; Daria Motamedi; Jack Youngren; George V Thomas; Jiaoti Huang; Rahul Aggarwal; Joshi J Alumkal; Tomasz M Beer; Eric J Small; Thomas M Link
Journal:  J Vasc Interv Radiol       Date:  2017-05-24       Impact factor: 3.464

5.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

6.  GeneHancer: genome-wide integration of enhancers and target genes in GeneCards.

Authors:  Simon Fishilevich; Ron Nudel; Noa Rappaport; Rotem Hadar; Inbar Plaschkes; Tsippi Iny Stein; Naomi Rosen; Asher Kohn; Michal Twik; Marilyn Safran; Doron Lancet; Dana Cohen
Journal:  Database (Oxford)       Date:  2017-01-01       Impact factor: 3.451

7.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Authors:  David T W Jones; Sylvia Kocialkowski; Lu Liu; Danita M Pearson; L Magnus Bäcklund; Koichi Ichimura; V Peter Collins
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

8.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.

Authors:  Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz
Journal:  Nat Biotechnol       Date:  2013-02-10       Impact factor: 54.908

9.  The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer.

Authors:  John R Prensner; Anirban Sahu; Matthew K Iyer; Rohit Malik; Benjamin Chandler; Irfan A Asangani; Anton Poliakov; Ismael A Vergara; Mohammed Alshalalfa; Robert B Jenkins; Elai Davicioni; Felix Y Feng; Arul M Chinnaiyan
Journal:  Oncotarget       Date:  2014-03-30

10.  The long tail of oncogenic drivers in prostate cancer.

Authors:  Joshua Armenia; Stephanie A M Wankowicz; David Liu; Jianjiong Gao; Ritika Kundra; Ed Reznik; Walid K Chatila; Debyani Chakravarty; G Celine Han; Ilsa Coleman; Bruce Montgomery; Colin Pritchard; Colm Morrissey; Christopher E Barbieri; Himisha Beltran; Andrea Sboner; Zafeiris Zafeiriou; Susana Miranda; Craig M Bielski; Alexander V Penson; Charlotte Tolonen; Franklin W Huang; Dan Robinson; Yi Mi Wu; Robert Lonigro; Levi A Garraway; Francesca Demichelis; Philip W Kantoff; Mary-Ellen Taplin; Wassim Abida; Barry S Taylor; Howard I Scher; Peter S Nelson; Johann S de Bono; Mark A Rubin; Charles L Sawyers; Arul M Chinnaiyan; Nikolaus Schultz; Eliezer M Van Allen
Journal:  Nat Genet       Date:  2018-04-02       Impact factor: 38.330

View more
  164 in total

Review 1.  Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors:  Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

Review 2.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

3.  Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.

Authors:  William S Chen; Rahul Aggarwal; Li Zhang; Shuang G Zhao; George V Thomas; Tomasz M Beer; David A Quigley; Adam Foye; Denise Playdle; Jiaoti Huang; Paul Lloyd; Eric Lu; Duanchen Sun; Xiangnan Guan; Matthew Rettig; Martin Gleave; Christopher P Evans; Jack Youngren; Lawrence True; Primo Lara; Vishal Kothari; Zheng Xia; Kim N Chi; Robert E Reiter; Christopher A Maher; Felix Y Feng; Eric J Small; Joshi J Alumkal
Journal:  Eur Urol       Date:  2019-03-28       Impact factor: 20.096

Review 4.  Targeting the androgen receptor and overcoming resistance in prostate cancer.

Authors:  David J Einstein; Seiji Arai; Steven P Balk
Journal:  Curr Opin Oncol       Date:  2019-05       Impact factor: 3.645

5.  Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.

Authors:  Paymaneh D Malihi; Ryon P Graf; Angel Rodriguez; Naveen Ramesh; Jerry Lee; Ramsay Sutton; Rhett Jiles; Carmen Ruiz Velasco; Emi Sei; Anand Kolatkar; Christopher Logothetis; Nicholas E Navin; Paul Corn; Ana M Aparicio; Ryan Dittamore; James Hicks; Peter Kuhn; Amado J Zurita
Journal:  Clin Cancer Res       Date:  2020-04-27       Impact factor: 12.531

6.  The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer.

Authors:  Susmita G Ramanand; Yong Chen; Jiapei Yuan; Kelly Daescu; Maryou Bk Lambros; Kathleen E Houlahan; Suzanne Carreira; Wei Yuan; GuemHee Baek; Adam Sharp; Alec Paschalis; Mohammed Kanchwala; Yunpeng Gao; Adam Aslam; Nida Safdar; Xiaowei Zhan; Ganesh V Raj; Chao Xing; Paul C Boutros; Johann de Bono; Michael Q Zhang; Ram S Mani
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

7.  Cancer transcriptomic profiling from rapidly enriched circulating tumor cells.

Authors:  Gareth J Morrison; Alexander T Cunha; Nita Jojo; Yucheng Xu; Yili Xu; Eric Kwok; Peggy Robinson; Tanya Dorff; David Quinn; John Carpten; Zarko Manojlovic; Amir Goldkorn
Journal:  Int J Cancer       Date:  2020-02-27       Impact factor: 7.396

Review 8.  Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2019-12-11       Impact factor: 4.104

9.  Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.

Authors:  Yingming Li; Rendong Yang; Christine M Henzler; Yeung Ho; Courtney Passow; Benjamin Auch; Suzanne Carreira; Daniel Nava Rodrigues; Claudia Bertan; Tae Hyun Hwang; David A Quigley; Ha X Dang; Colm Morrissey; Michael Fraser; Stephen R Plymate; Christopher A Maher; Felix Y Feng; Johann S de Bono; Scott M Dehm
Journal:  Clin Cancer Res       Date:  2020-01-13       Impact factor: 12.531

Review 10.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.